A phase I, two-center, open-label, dose-escalating study to investigate the safety, tolerability and immunogenicity of pPJV7630, a therapeutic DNA vaccine for herpes simplex virus type 2 (HSV-2), in patients with recurrent genital Herpes caused by HSV-2
Latest Information Update: 30 Mar 2007
Price :
$35 *
At a glance
- Drugs Herpes simplex virus DNA vaccine (Primary)
- Indications Herpes genitalis; Herpes simplex virus type 2 infections
- Focus Adverse reactions
- 30 Mar 2007 Status change
- 28 Mar 2007 New trial record.